AC Immune SA filings document a foreign private issuer developing precision therapeutics and diagnostics for neurodegenerative diseases. Recent Form 6-K reports furnish press releases, IFRS financial statements, management discussion and annual statutory and compensation reports, with certain reports incorporated by reference into Form F-3 and Form S-8 registration statements.
The disclosures cover clinical and trial updates for ACI-24, ACI-7104.056, ACI-19764 and ACI-35.030/JNJ-2056; collaboration amendments for Morphomer® Tau small molecules; cash resources and operating requirements; and governance-related compensation reporting. They also record exhibit-based material updates for AC Immune’s active immunotherapy, small-molecule and diagnostic pipeline.
AC Immune SA reported that it has positive interim safety and immunogenicity data from the Phase 2 VacSYn clinical trial of ACI-7104.056, its wholly owned anti‑alpha‑synuclein active immunotherapy for early Parkinson’s disease. The trial is evaluating this candidate in patients with early-stage Parkinson’s.
The company disclosed that these results were first shared in a press release dated December 11, 2025, which is attached as an exhibit to this Form 6-K for more detailed information.
AC Immune SA (ACIU) submitted a Form 144 notifying the proposed sale of 45,000 common shares through Morgan Stanley Smith Barney LLC on or about 10/03/2025 with an aggregate market value of $140,850.00. The filer acquired these shares on 06/01/2012 by previously exercised stock options and paid cash for them. The filing lists recent sales by the same account under 10b5-1 plans totaling multiple transactions between 07/24/2025 and 09/29/2025, including sales of 29,400 and 5,600 shares on 09/25/2025 and 09/29/2025, respectively. The filer attests no undisclosed material adverse information and includes standard Rule 144 representations.
AC Immune SA reports the outcome of a strategic review, deciding to concentrate spending on its most important R&D assets. The focus will be on three clinical-stage active immunotherapy programs, including two in collaborations with pharmaceutical partners, and on small molecule programs targeting NLRP3 and Tau.
To support this sharper focus, AC Immune plans to reduce its workforce by around 30%. The company states that these actions are expected to extend its available cash for operations to the end of the third quarter of 2027, giving it more time to advance its key pipeline programs.